Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis

By sjmartinez • July 16, 2024

Paik JJ, Vencovský J, Charles-Schoeman C, Wright GC, Vleugels RA, Goriounova AS, Mudd PN Jr, Aggarwal R. Brepocitinib, a potent and selective TYK2/JAK1 inhibitor: scientific and clinical rationale for dermatomyositis. Clin Exp Rheumatol. 2024 Jul 15. doi: 10.55563/clinexprheumatol/eeglsa. Epub ahead of print. PMID: 39008325.

Tags: Publications, Rheumatology

Physician turnover rates and job stability in interventional spine and pain practices: Results of an IPSIS survey study

Chen AS, Leet JG, Schneider B, Teramoto M, Abdullah NM, McCormick ZL. Physician turnover rates and job stability in interventional spine and pain practices: Results[...]

Plea to radiologists: Please consider Mahvash disease when encountering an enlarged pancreas

Yu R. Plea to radiologists: Please consider Mahvash disease when encountering an enlarged pancreas. World J Radiol. 2024 Aug 28;16(8):371-374. doi: 10.4329/wjr.v16.i8.371. PMID: 39239240; PMCID:[...]

Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review

Good SD, Sparks JA, Volkmann ER. Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review. Rev Colomb Reumatol. 2024[...]